ZP1848

  • 2010

    8. juni 2010:Pressemeddelelse nr. 5, 2010: Zealand Pharma Announces An Extension of The Lixisenatide...

    Read More >

  • Meet us

    The 31st European Peptide Symposium, Copenhagen, Denmark, 5-9 September 2010 (Science) 46th An...

    Read More >

ZP1848

Glucagon-like Peptide-2 (GLP-2) is a peptide growth factor that specifically targets and stimulates growth of the intestinal epithelium. In experimental models of small intestinal injury and disease, administration of GLP-2 remarkably enhanced the repair, regeneration and absorptive capacity of the small intestinal mucosa. These findings aroused significant interest for the potential therapeutic use of GLP-2 in the treatment of intestinal disease and injury although the known relative instability of the peptide in the body represented a significant challenge.

ZP1848 is a SIP® modified novel GLP-2 peptide analogue with enhanced stability and efficacy. In pre-clinical pharmacological studies ZP1848 has been shown to attenuate small intestinal inflammation and enhance recovery from inflammation in an experimental model of Inflammatory Bowel Diseases (IBD).

Our objective is to develop ZP1848 as a mucosal regeneration-enhancing agent to be used for induction of remission and in the prevention of relapses in IBD patients.

A Phase Ia study in healthy volunteers and a Phase Ib study in Chrohn's patients in US are currently in the reporting phase.

To top of page

Tip a friend

Fill in the form below to tip a friend about this page.






Subscribe

When this page is updated you will be updated by e-mail.



Related links